# China NMPA Drug Inspection - Guangdong Hongying Technology Co., Ltd. - Chloramphenicol eye drops

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guangdong-hongying-technology-co-ltd/8411179a-9efa-45dc-8ce5-4e7281d045b9/
Source feed: China

> China NMPA drug inspection for Guangdong Hongying Technology Co., Ltd. published November 30, 2017. Drug: Chloramphenicol eye drops. The Guangxi Zhuang Autonomous Region Food and Drug Administration (GXFDA) issued its 10th Drug Quality Announcement on N

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Bulletin of Guangxi Zhuang Autonomous Region Food and Drug Administration (Issue 10, 2017, Serial No. 51)
- Company Name: Guangdong Hongying Technology Co., Ltd.
- Publication Date: 2017-11-30
- Drug Name: Chloramphenicol eye drops
- Inspection Finding: [Inspection] Related substances do not meet regulations.
- Action Taken: Necessary control measures such as sealing up, seizing, and suspending sales will be implemented, and the units responsible for the source of the inspected goods will be investigated and dealt with in accordance with the law.
- Summary: The Guangxi Zhuang Autonomous Region Food and Drug Administration (GXFDA) issued its 10th Drug Quality Announcement on November 30, 2017, following a comprehensive drug sampling plan. The initiative focused on strengthening drug quality supervision to safeguard public health. The announcement reported that five batches of drug preparations failed to meet quality standards during inspections.

Specifically, Guangxi Hongying Technology Co., Ltd. was identified for four batches of Chloramphenicol Drops (batches 16102301, 16113001, 16101101, 17010501), which were found to have non-compliant related substances, indicating impurity issues. Additionally, the Liuzhou Traditional Chinese Medicine Hospital Preparation Room's Nanxilin solution (batch 20170313) failed to meet content volume specifications, suggesting an inaccurate active ingredient dosage.

These inspections were conducted based on the Guangxi Drug Sampling Plan and in accordance with the Chinese Pharmacopoeia (2015 edition). In response to these findings, the GXFDA has mandated immediate control measures, including sealing, seizing, and suspending the sale of the substandard drugs. The agency is also pursuing investigations and legal actions against the responsible entities to address these quality violations.

Company: https://www.globalkeysolutions.net/companies/guangdong-hongying-technology-co-ltd/57ef3f02-0180-4397-8d8e-668004e0c3b0/